FDA Approves New Indication for Delafloxacin for CABP |
News and Updates
eMediNexus Coverage from: 
FDA Approves New Indication for Delafloxacin for CABP
eMediNexus,  27 October 2019
remove_red_eye 502 Views
#Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Pulmonary Medicine

0 Read Comments                

The US Food and Drug Administration (FDA) has approved delafloxacin (Baxdela, Melinta Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria, according to a company news release.

This is the second indication for the fluoroquinolone antibiotic. Approval of delafloxacin for CABP was based on positive results from a phase 3, randomized, double-blind trial comparing the efficacy and safety of delafloxacin to moxifloxacin… (Medscape)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now